20.46
price down icon6.75%   -1.48
after-market  After Hours:  20.46 
loading
Phreesia Inc stock is currently priced at $20.46, with a 24-hour trading volume of 591.30K. It has seen a -6.75% decreased in the last 24 hours and a -11.08% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $22.24 pivot point. If it approaches the $19.87 support level, significant changes may occur.
Previous Close:
$21.94
Open:
$21.44
24h Volume:
591.30K
Market Cap:
$1.15B
Revenue:
$356.30M
Net Income/Loss:
$-136.89M
P/E Ratio:
-7.1538
EPS:
-2.86
Net Cash Flow:
$-57.48M
1W Performance:
-9.55%
1M Performance:
-11.08%
6M Performance:
+53.37%
1Y Performance:
-37.62%
1D Range:
Value
$20.27
$21.69
52W Range:
Value
$12.05
$34.98

Phreesia Inc Stock (PHR) Company Profile

Name
Name
Phreesia Inc
Name
Phone
888-654-7473
Name
Address
432 Park Avenue South, 12th Floor Between 29th & 30th Streets, New York
Name
Employee
436
Name
Twitter
@phreesia
Name
Next Earnings Date
2024-03-14
Name
Latest SEC Filings
Name
PHR's Discussions on Twitter

Phreesia Inc Stock (PHR) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-26-24 Initiated Truist Buy
Jan-17-24 Upgrade DA Davidson Neutral → Buy
Jan-03-24 Initiated Barclays Overweight
Apr-12-23 Initiated Stephens Overweight
Jan-04-23 Reiterated Needham Buy
Dec-13-22 Upgrade Citigroup Neutral → Buy
Dec-09-22 Upgrade SVB Leerink Mkt Perform → Outperform
Oct-13-22 Initiated DA Davidson Neutral
Sep-16-22 Initiated KeyBanc Capital Markets Overweight
Apr-14-22 Initiated Guggenheim Buy
Jan-06-22 Downgrade SVB Leerink Outperform → Mkt Perform
Dec-02-21 Initiated Jefferies Buy
Sep-02-21 Reiterated Needham Buy
Aug-27-21 Initiated Canaccord Genuity Buy
Jul-13-21 Initiated JMP Securities Mkt Outperform
Jun-08-21 Initiated Berenberg Buy
Apr-29-21 Resumed JP Morgan Overweight
Apr-01-21 Initiated Robert W. Baird Outperform
Nov-11-20 Initiated Stephens Overweight
Oct-27-20 Initiated Needham Buy
Sep-22-20 Initiated DA Davidson Buy
Jul-14-20 Initiated Citigroup Neutral
May-15-20 Initiated Guggenheim Buy
Apr-21-20 Initiated RBC Capital Mkts Sector Perform
Apr-13-20 Initiated SVB Leerink Outperform
Jan-31-20 Initiated KeyBanc Capital Markets Overweight
Jan-09-20 Initiated Cantor Fitzgerald Overweight
Dec-20-19 Initiated Raymond James Outperform
Oct-11-19 Initiated Robert W. Baird Outperform
Aug-13-19 Initiated JP Morgan Overweight
Aug-12-19 Initiated Piper Jaffray Overweight
Aug-12-19 Initiated Wells Fargo Outperform
Aug-12-19 Initiated William Blair Outperform
Jul-23-19 Initiated Chardan Capital Markets Buy
View All

Phreesia Inc Stock (PHR) Financials Data

Phreesia Inc (PHR) Revenue 2024

PHR reported a revenue (TTM) of $356.30 million for the quarter ending January 31, 2024, a +26.84% rise year-over-year.
loading

Phreesia Inc (PHR) Net Income 2024

PHR net income (TTM) was -$136.88 million for the quarter ending January 31, 2024, a +22.29% increase year-over-year.
loading

Phreesia Inc (PHR) Cash Flow 2024

PHR recorded a free cash flow (TTM) of -$57.48 million for the quarter ending January 31, 2024, a +50.59% increase year-over-year.
loading

Phreesia Inc (PHR) Earnings per Share 2024

PHR earnings per share (TTM) was -$2.51 for the quarter ending January 31, 2024, a +25.30% growth year-over-year.
loading
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company's Phreesia Platform offers a suite of solutions to manage the patient intake process and an integrated payments solution for processing of patient payments. It deploys its platform in a range of modalities, including through Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a Web-based dashboard for providers; PhreesiaPads, which are self-service intake tablets; and Arrivals Stations that are on-site kiosks. The company's Phreesia Platform provides a registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, and cost estimation tools; clinical support solution that collects clinical intake and PRO data for approximately 25 specialties; appointments solution for online appointments, reminders, and referral tracking; and life sciences solution to deliver targeted and clinically relevant marketing content to patients. It serves patients, healthcare provider organizations, and life sciences companies. The company was founded in 2005 and is headquartered in New York, New York.
$16.30
price down icon 0.91%
$7.08
price up icon 1.72%
$32.50
price down icon 0.31%
health_information_services TXG
$26.90
price down icon 2.25%
health_information_services EVH
$28.32
price down icon 3.21%
$23.59
price down icon 1.34%
Cap:     |  Volume (24h):